WO2008121261A3 - Traitement efficace de tumeurs et de cancer au moyen de promédicaments de la triciribine - Google Patents

Traitement efficace de tumeurs et de cancer au moyen de promédicaments de la triciribine Download PDF

Info

Publication number
WO2008121261A3
WO2008121261A3 PCT/US2008/003853 US2008003853W WO2008121261A3 WO 2008121261 A3 WO2008121261 A3 WO 2008121261A3 US 2008003853 W US2008003853 W US 2008003853W WO 2008121261 A3 WO2008121261 A3 WO 2008121261A3
Authority
WO
WIPO (PCT)
Prior art keywords
prodrugs
tumors
cancer
treatment
triciribin
Prior art date
Application number
PCT/US2008/003853
Other languages
English (en)
Other versions
WO2008121261A2 (fr
Inventor
Lawrence Akinsanmi
Original Assignee
Vioquest Pharmaceuticals Inc
Lawrence Akinsanmi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vioquest Pharmaceuticals Inc, Lawrence Akinsanmi filed Critical Vioquest Pharmaceuticals Inc
Publication of WO2008121261A2 publication Critical patent/WO2008121261A2/fr
Publication of WO2008121261A3 publication Critical patent/WO2008121261A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux promédicaments de la triciribine et de substances apparentées, ainsi que des régimes thérapeutiques de promédicaments de la triciribine et de substances apparentées et des compositions pour le traitement de tumeurs, de cancer et d'autres troubles associés à une prolifération cellulaire anormale. L'invention concerne en outre des formulations orales de promédicaments à biodisponibilité accrue, fournissant ainsi une nouvelle voie d'administration avec les avantages cliniques qui en découlent en termes de facilité d'administration.
PCT/US2008/003853 2007-03-28 2008-03-25 Traitement efficace de tumeurs et de cancer au moyen de promédicaments de la triciribine WO2008121261A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90730507P 2007-03-28 2007-03-28
US60/907,305 2007-03-28

Publications (2)

Publication Number Publication Date
WO2008121261A2 WO2008121261A2 (fr) 2008-10-09
WO2008121261A3 true WO2008121261A3 (fr) 2008-12-24

Family

ID=39712321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003853 WO2008121261A2 (fr) 2007-03-28 2008-03-25 Traitement efficace de tumeurs et de cancer au moyen de promédicaments de la triciribine

Country Status (2)

Country Link
TW (1) TW200902034A (fr)
WO (1) WO2008121261A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2841075T (pt) * 2012-04-26 2020-06-25 Massachusetts Gen Hospital Agentes e métodos para tratamento e prevenção de queratose seborreica
US10508309B2 (en) 2013-05-17 2019-12-17 The General Hospital Corporation Methods for detecting and treating variants of seborrheic keratoses
US11058704B2 (en) * 2016-10-03 2021-07-13 Arcus Biosciences, Inc. Inhibitors of adenosine 5′-nucleotidase
US20220395575A1 (en) * 2019-11-14 2022-12-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapy with protein kinase b activation inhibitor to treat cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4123524A (en) * 1977-06-08 1978-10-31 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 6-amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-C]pyridazine-5'-phosphate as a novel compound and its utility against L-1210 mouse leukemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4123524A (en) * 1977-06-08 1978-10-31 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 6-amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-C]pyridazine-5'-phosphate as a novel compound and its utility against L-1210 mouse leukemia

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. J. BODNER ET AL.: "Induction of differentiation of human promyelocytic leukemia cells (HL-60) by nucleosides and methotrexate", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 67, no. 5, 1981, US DEPT. OF HEALTH, EDUCATION AND WELFARE, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH, BETHESDA, MD; US, pages 1025 - 1030 *
A. R. PORCARI ET AL.: "An Improved Total Synthesis of Triciribine: A Tricyclic Nucleoside with Antineoplastic and Antiviral Properties", NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS., vol. 23, no. 1, 2004, TAYLOR & FRANCIS, PHILADELPHIA, PA.; US, pages 31 - 39 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 12 May 1984 (1984-05-12), XP002499547, retrieved from STN Database accession no. 1982:32363 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 18 February 2004 (2004-02-18), XP002499546, retrieved from STN Database accession no. 2004:131615 *
PORCARI, A. R. ET AL.: "6-N-Acyltriciribine Analogues: Structure-Activity Relationship between Acyl Carbon Chain Length and Activity against HIV-1", JOURNAL OF MEDICINAL CHEMISTRY., vol. 43, no. 12, 2000, AMERICAN CHEMICAL SOCIETY. WASHINGTON; US, pages 2457 - 2463, XP002499362 *

Also Published As

Publication number Publication date
TW200902034A (en) 2009-01-16
WO2008121261A2 (fr) 2008-10-09

Similar Documents

Publication Publication Date Title
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
WO2009064460A3 (fr) Systèmes de délivrance aux voies gastro-intestinales
MX2010005931A (es) Profarmacos de tetrahidrocanabinol, composiciones que comprenden profarmacos de tetrahidrocanabinol y metodos para utilizar los mismos.
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
HK1144390A1 (en) Compositions for the treatment of neoplastic diseases
HK1157337A1 (fr)
EP4289838A3 (fr) Dérivés d'arylméthoxy isoindoline substitués, compositions les comportant et procédés d'utilisation associés
WO2008028193A3 (fr) Formulations orales d'analogues de cytidine administrées dans le côlon
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
WO2005116086A3 (fr) Glucosamine et promédicaments mutuels anti-inflammatoires, compositions et procédés à base de glucosamine
EP2166837A4 (fr) Combinaison médicamenteuse utilisable pour le traitement de troubles cutanés
MX2009002666A (es) Compuestos de n-metilaminometil isoindol, composiciones que los comprenden y metodos que utilizan los mismos.
WO2009071480A3 (fr) Dérivés de dihydroptéridin-6-one substitués, procédé de préparation desdits dérivés et leur utilisation en tant qu'inhibiteurs de kinase
WO2008097924A3 (fr) Compositions pharmaceutiques comprenant des analogues du dextrométhorphane pour le traitement de troubles neurologiques
AU2008339918A1 (en) Medicament for the treatment of cancer of the pancreas
TN2011000172A1 (en) Therapeutic antiviral peptides
WO2008020027A3 (fr) Utilisation de composés et de dérivés du 2,5-dihydroxybenzène pour le traitement du cancer de la peau
MY145795A (en) Pyrazoline compounds
WO2010121164A3 (fr) Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
WO2011150201A3 (fr) Composés azolylamide et leurs procédés d'utilisation
HK1142823A1 (en) Formulations for the oral administration of therapeutic agents and related methods
MX2012007217A (es) Derivados de (metilsulfonil) etilbenceno isoindolina y sus usos terapeuticos.
MX2010001243A (es) Composicion anti-inflamatoria.
WO2008121261A3 (fr) Traitement efficace de tumeurs et de cancer au moyen de promédicaments de la triciribine
WO2008004100A9 (fr) Composés thérapeutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08742227

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1)EPC (EPOFORM 1205A DATED 08.03.2010

122 Ep: pct application non-entry in european phase

Ref document number: 08742227

Country of ref document: EP

Kind code of ref document: A2